Menu

UK scraps nationality DNA-testing

The UK’s immigration agency has abandoned a program to develop DNA and isotope testing to assess the nationality of asylum seekers.

Jun 20, 2011
Tia Ghose

Perfomers celebrate Refugee Week, LondonGARRYKNIGHT VIA FLICKR

The UK’s immigration agency has canceled a widely derided program to use DNA to verify the nationality claims of asylum seekers. The Human Provenance Pilot Project aimed to determine if asylum seekers allegedly fleeing persecution in war-torn Somalia, for instance, were actually citizens of neighboring African countries using the nearby unrest as an excuse to enter the United Kingdom.

Scientists called the program “horrifying,” “naïve,” and “flawed” when its existence was first revealed in 2009. DNA can reveal ancestry, but not nationality, because “genes don’t respect national borders,” David Balding, a population geneticist at Imperial College London, told ScienceInsider. The agency also hoped isotope testing could prove nationality claims, by matching chemical ratios in an asylum seeker’s hair or nails with those found in certain countries. But experts said isotope ratios in those tissues would reflect, at most, the past year of a person’s life.

The failed program, which reportedly cost £190,000 (about US$300,000), was canceled in March, and there are no plans to evaluate data collected for the effort, an agency spokesman told ScienceInsider.

 

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the extension of its CRISPR Screening Service to includeex vivoT lymphocytes. The service extension meets the requirements of immunology-based research in drug discovery,enabling new gene targets to be identified in biologically and potentially therapeutically relevant settings.
pIC50: The Advantages of Thinking Logarithmically
pIC50: The Advantages of Thinking Logarithmically
Watch this webinar from Collaborative Drug Discovery to learn about how using pIC50 helps you get a better sense of the relative potencies, calculate the correct mean of multiple values, and select better sampling doses.
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.